News CervoMed Inc.

Equities

CRVO

US15713L1098

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
24.45 ^USD	-0.85%		+0.49%	+220.45%

Apr. 08	Canaccord Genuity Adjusts Price Target on CervoMed to $65 From $50, Maintains Buy Rating	MT
Mar. 29	CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CervoMed : Nominating and Corporate Governance Committee Charter	May. 05	PU
CervoMed : Corporate Presentation April 2024	Apr. 21	PU
Canaccord Genuity Adjusts Price Target on CervoMed to $65 From $50, Maintains Buy Rating	Apr. 08	MT
CervoMed : Corporate Presentation April 2024	Apr. 03	PU
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	Apr. 01	AQ
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
CervoMed to Participate in Upcoming Investor Conferences	Mar. 28	AQ
CervoMed Prices $50 Million Equity Sale to Private Investors	Mar. 28	MT
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors	Mar. 28	AQ
CervoMed Inc. announced that it expects to receive $49.999967 million in funding	Mar. 27	CI
CervoMed : Shareholder Meeting - Form 8-K	Mar. 18	PU
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024	Mar. 05	AQ
CervoMed to Participate in the BIO CEO and Investor Conference	Feb. 21	AQ
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board	Feb. 20	AQ
Canaccord Genuity Starts CervoMed With Buy Rating, $50 Price Target	Feb. 15	MT
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	Feb. 12	AQ
Cervomed Inc. Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal That Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	Feb. 12	CI
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board	Feb. 07	AQ
CervoMed Inc. Announces Appointment of Joshua Boger, Ph.D., to its Board of Directors and as Chair of the Board	Feb. 07	CI
CervoMed to Participate in the Emerging Growth Conference 67	Feb. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CervoMed Inc.

Equities

CRVO

US15713L1098

Summary

Filters